100896-08-0

Basic information

• Product Name: 3-(9-ANTHRYL)-L-ALANINE
• Synonyms: 3-ALA(9-ANTHRYL)-OH;L-3-(9-ANTHRYL)ALANINE;3-(9-Anthryl)-L-alanine99%;3-(9-ANTHRYL)-L-ALANINE
• CAS NO: 100896-08-0
• Molecular Formula: C17H15NO2
• Molecular Weight: 265.31
• Mol File: 100896-08-0.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 503.4±38.0 °C(Predicted)
• Appearance: /
• Density: 1.289±0.06 g/cm3(Predicted)
• Storage Temp.: Store at 0-5°C
• PKA: 2.21±0.30(Predicted)
• CAS DataBase Reference: 3-(9-ANTHRYL)-L-ALANINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(9-ANTHRYL)-L-ALANINE(100896-08-0)
• EPA Substance Registry System: 3-(9-ANTHRYL)-L-ALANINE(100896-08-0)

Safety Data

• Hazardous Substances Data: 100896-08-0(Hazardous Substances Data)

Usage

General Description

3-(9-anthryl)-L-alanine is a chemical compound derived from the amino acid L-alanine and the polycyclic aromatic hydrocarbon 9-anthryl. It is commonly used in the field of photochemistry as a probe to study the environment and dynamics of proteins and peptides, due to its strong fluorescence and high sensitivity to its microenvironment. 3-(9-ANTHRYL)-L-ALANINE has been employed in various biochemical and pharmaceutical research studies, including protein structure determination, drug delivery systems, and the study of molecular interactions. Its unique properties make it a valuable tool for investigating the behavior of biological molecules and developing new therapeutic strategies.

Upstream product

• 24463-19-2 anthracenylmethyl chloride 
• 2584-59-0 -acetamino-malonsaeure-dimethylester 

Downstream Products

• 190319-98-3 3-Anthracen-9-yl-2-tert-butoxycarbonylamino-propionic acid 

Relevant articles and documents

Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists

Nonapeptide and decapeptide analogs of LHRH which have the formula: STR1 and the pharmaceutically acceptable salts thereof, wherein: X is a D-alanyl residue wherein one hydrogen on C-3 is replaced by:(a) a carbocyclic aryl-containing radical selected from the group consisting of phenyl substituted with three or more straight chain lower alkyl groups, naphthyl, anthryl, fluorenyl, phenanthryl, biphenylyl and benzhydryl; or(b) a saturated carbocyclic radical selected from the group consisting of cyclohexyl substituted with three or more straight chain lower alkyl groups, perhydronaphthyl, perhydrobiphenylyl, perhydro-2,2-diphenylmethyl, and adamantyl; or(c) a heterocyclic aryl containing radical selected from the group consisting of radicals represented by the following structural formulas: STR2 wherein A"" and A'' are independently selected from the group consisting of hydrogen, lower alkyl, chlorine, and bromine, and G is selected from the group consisting of oxygen, nitrogen, and sulfur;A is an aminoacyl residue selected from the group consisting of L-pyroglutamyl, D-pyroglutamyl, N-acyl-L-prolyl, N-acyl-D-prolyl, N-acyl-D-tryptophanyl, N-acyl-D-phenylalanyl, N-acyl-D-p-halophenylalanyl, and N-acyl-X wherein X is as defined previously;B is an amino acyl residue selected from the group consisting of D-phenylalanyl, D-p-halophenylalanyl, 2,2-diphenylglycyl, and X wherein X is as defined previously;C is an amino acyl residue selected from the group consisting of L-tryptophanyl, D-tryptophanyl, D-phenylalanyl and X wherein X is as defined above;E is glycinamide or --NH--R 1, wherein R 1 is lower alkyl, cycloalkyl, fluoro lower alkyl or STR3 wherein R 2 is hydrogen or lower alkyl; are disclosed. These compounds are LHRH antagonists.